Stocks:
5,168
ETFs:
2,288
Exchanges:
11
Market Cap:
$63.92T
24h Vol:
$4.36B
Dominance:
MSFT:4.92%
Stocklytics Platform
Instrument logo  ONTX
Onconova Therapeutics Inc
ONTX
52 / 100
Penny Stock
$0.74arrow_drop_down5.91%-$0.04

Performance History

Stocklytics logo
Key Stats
Open$0.78
Prev. Close$0.78
EPS-0.96
DividendNon-Dividend
Next Earnings Date-
Dividend Yield %-
Market Cap20904684.00
PE Ratio-
LOWHIGH
Day Range0.74
0.79
52 Week Range0.55
1.45
Ratios
P/B Ratio1.86
Revenue-
Operating M. %-8,928.07%
Earnings$0.00
Earnings Growth %0.08%
EBITDA Margin %-
ROE %-84.30%
EPS-0.96

Score Breakdown

52vs 55. Market Avg.

All Score 52 / 100 is to help users identify stocks that trade at a low value relative to their fundamentals. Suitable for value investors such as Warren Buffet.

ONTXMARKET
Value7040
Quality3340
Ownership317
Growth4645
Dividends-38
check_circle

Onconova Therapeutics Inc's Price discount from all time high of 100% is great compared to market average of 42.36%. This indicates ONTX could be a good value stock.

Financial Forecast

AI Price Prediction

line chart placeholder

Analyst Ratings

info
Analyst ratings for this stock instrument are based on analysts' assumptions and should not be solely relied upon for financial decisions.

Correlated Companies

PRICE$751.62
24H (%)arrow_drop_down1.04%
24H ($)-$7.97
MARKET CAP$724.46B
PRICE$438.91
24H (%)arrow_drop_down0.63%
24H ($)-$2.81
MARKET CAP$414.91B
PRICE$147.57
24H (%)arrow_drop_down0.81%
24H ($)-$1.21
MARKET CAP$361.94B
PRICE$126.33
24H (%)arrow_drop_up0.14%
24H ($)$0.18
MARKET CAP$321.01B

About Onconova Therapeutics Inc (ONTX)

Onconova Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel products to treat cancer in the United States. It has two clinical-stage programs, including narazaciclib, a multi-targeted kinase inhibitor that is in Phase I study for solid tumors, as well as hematological malignancies as a single agent or in combination with other anti-cancer therapies; and oral rigosertib alone or in combination with PD-1 inhibitor, which is in Phase I/IIa study for the treatment of progressive K-Ras mutated non-small cell lung cancer. The company also conducting a Phase II investigator-initiated study with rigosertib monotherapy in patients with advanced/metastatic squamous cell carcinoma associated with recessive dystrophic epidermolysis bullosa. It has a license and collaboration agreement with HanX Biopharmaceuticals, Inc. for the development, registration, and commercialization of narazaciclib in China. Onconova Therapeutics, Inc. was incorporated in 1998 and is headquartered in Newtown, Pennsylvania.

Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Steven M. Fruchtman M.D.
Headquarters
Newtown
Employees
16
Exchange
NASDAQ
add Onconova Therapeutics Inc to watchlist

Keep an eye on Onconova Therapeutics Inc

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help
What is Onconova Therapeutics Inc's (ONTX) price per share?

The current price per share for Onconova Therapeutics Inc (ONTX) is $0.74. The stock has seen a price change of -$0.05 recently, indicating a -5.91% change. This reflects the stock's recent market performance and investor sentiment.

help
What is the 52-week high and low for Onconova Therapeutics Inc (ONTX)?

For Onconova Therapeutics Inc (ONTX), the 52-week high is $1.45, which is 95.95% from the current price. The 52-week low is $0.55, the current price is 34.55% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

help
Is Onconova Therapeutics Inc (ONTX) a growth stock?

Onconova Therapeutics Inc (ONTX) has shown an average price growth of -44.66% over the past three years. It has received a score of 9 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Onconova Therapeutics Inc as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

help
What is Onconova Therapeutics Inc (ONTX) stock price performance year to date (YTD)?

As of the latest data, Onconova Therapeutics Inc (ONTX) has a year-to-date price change of -7.38%. Over the past month, the stock has experienced a price change of -23.44%. Over the last three months, the change has been 6.61%. Over the past six months, the figure is 10.43%. Looking at a longer horizon, the five-year price change stands at -98.76%.

help
Is Onconova Therapeutics Inc (ONTX) a profitable company?

Onconova Therapeutics Inc (ONTX) has a net income of -$18.95M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of -8.93K% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at , although specific revenue growth data is currently not available. The gross profit is $226B. Operating income is noted at -$20.3M. Furthermore, the EBITDA is -$21.55M.

help
What is the market capitalization of Onconova Therapeutics Inc (ONTX)?

Onconova Therapeutics Inc (ONTX) has a market capitalization of $20.9M. The average daily trading volume is 363.76K, indicating the stock's liquidity and investor engagement.

News

email

Sign up for our newsletter

Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.

Approach investments with caution like a driver who slows down on a curvy road.